Method for synthesizing and preparing tenofovir
By using cheap sodium tert-butoxide and magnesium chloride catalysts, as well as low boiling solvents isopropanol or tert-butanol, the synthesis process of tenofovir was optimized, and the problems of high cost and low efficiency in the existing processes were solved, achieving the More efficient and economical production.
Patent Information
- Application Number
- CN202411105203.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
AI Technical Summary
The basic catalyst used in the existing tenofovir synthesis process is relatively expensive and the reaction solvent DMF boiling point is high, resulting in high production costs and low efficiency.
The low-priced sodium tert-butoxide and magnesium chloride are used as catalysts, and low boiling point isopropanol or tert-butanol are used as reaction solvents to generate tenofovir diethyl ester through a warming reaction, which is then hydrolyzed and replaced by alkaline adjustment treatment. Norfovie.
It reduces production costs, improves production efficiency, shortens concentration time, reduces the possibility of impurities generation, and is suitable for commercial production.
Smart Images

Figure BDA0004990550420000011 
Figure BDA0004990550420000021 
Figure BDA0004990550420000022
Abstract
Description
Technical Field
[0001] The invention relates to a method for synthesizing tenofovir and belongs to the technical field of pharmaceuticals. Background Art
[0002] Tenofovir is a key intermediate of two APIs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF). Both are currently the first-line antiviral drugs used to treat HIV and HBV.
[0003]
[0004] It can be found from the structural formulas of the two raw materials that tenofovir is one of the key main fragments of the two drugs. Therefore, developing a tenofovir synthesis method with low cost, simple operation and good product quality can help provide the society, the country and the community with TDF and TAF drugs with good product quality and low price.
[0005] At present, the mainstream synthesis route of tenofovir is to use adenine and R-propylene carbonate as starting materials, and react under alkaline catalysis to obtain (R)-(+)-9-(2-hydroxypropyl) adenine (abbreviated as: HPA), which is then reacted with another key material diethyl p-toluenesulfonyloxymethylphosphonate (abbreviated as: DESMP) to obtain tenofovir diethyl ester (abbreviated as: DEP), and then hydrolyzed to obtain tenofovir:
[0006]
[0007] In the preparation of PMPA according to patent WO9804569A1, when preparing the intermediate DEP, DMF is used as a solvent and lithium tert-butoxide is used as a base (acidifying agent) to prepare DEP by a nucleophilic substitution reaction by heating. After the reaction is completed, it is neutralized with a weak acid, and N,N-dimethylformamide (abbreviated as: DMF, the same below) is concentrated under reduced pressure and then hydrolyzed to prepare PMPA:
[0008]
[0009] The synthesis process reported in patent US5733788A uses lithium hydride as an acidifying agent and DMF as a reaction solvent when preparing DEP. Similarly, after the reaction is completed, the acid is used for neutralization and the solvent is concentrated under reduced pressure before the next reaction.
[0010]
[0011] Patent US8049009B2 (Process for the preparation of Tenofovir
[0012] In the reported process for preparing TDF, magnesium tert-butoxide was used as an acidifying agent to prepare PMPA.
[0013]
[0014] Patent WO0208241 reported the production of TAF, using magnesium isopropoxide as the acidifying agent and DMF as the reaction solvent to prepare PMPA:
[0015]
[0016] The above literature reports that when selecting a base, lithium tert-butoxide, lithium hydride, magnesium tert-butoxide and magnesium isopropoxide are used as acidifying agents. The above bases are relatively expensive and have relatively strict requirements when used, thus increasing the production cost of PMPA.
[0017] In addition, when preparing DEP, all the above reports use DMF as the reaction solvent. After the reaction is completed, the DMF needs to be concentrated under reduced pressure at high temperature to obtain DMF. Since DMF has a high polarity and a high boiling point, high temperature and high vacuum conditions are required for the distillation of DMF.
[0018] Therefore, optimizing and changing the reaction solvent to a cheaper, easier solvent and one with a lower boiling point can reduce the PMPA production cost and improve production efficiency. Summary of the invention
[0019] The purpose of the present invention is to provide a method for synthesizing tenofovir which uses a low-cost acidifying agent and a reaction solvent to reduce production costs and ensure good product quality and high yield.
[0020] In order to achieve the above object, the technical solution adopted by the present invention is:
[0021] A method for synthesizing tenofovir comprises the following steps:
[0022] 1) Add (R)-9-(2-hydroxypropyl)adenine to an organic solvent solution containing a catalyst, and simultaneously add diethyl p-toluenesulfonyloxymethyl phosphate, and heat the reaction to generate tenofovir diethyl ester;
[0023] 2) Add strong acid to tenofovir diethyl ester and hydrolyze at elevated temperature to obtain tenofovir product;
[0024] 3) After the hydrolysis is completed, the reaction system is cooled and filtered to remove salt, and then the hydrochloric acid is concentrated and tenofovir is obtained after adjusting the base.
[0025] A further improvement of the technical solution of the present invention is as follows: in step (1), the catalyst is tert-butoxide base, and the catalyst is at least one of potassium tert-butoxide and sodium tert-butoxide; wherein the molar ratio of (R)-9-(2-hydroxypropyl)adenine to tert-butoxide base is 1.00:(1.00-4.00), preferably 1.0:(1.5-2.5), and most preferably 1.0:(1.8-2.2).
[0026] A further improvement of the technical solution of the present invention is as follows: in step (1), the catalyst is magnesium chloride, wherein the molar ratio of (R)-9-(2-hydroxypropyl)adenine to magnesium chloride is 1.0:(0.50-2.00), preferably 1.0:(0.8-1.6), and most preferably 1.0(1.0-1.2); the molar ratio of (R)-9-(2-hydroxypropyl)adenine to diethyl tosyloxymethyl phosphate is 1.0:(1.0-2.0), preferably 1.0:(1.0-1.5), and most preferably 1.0:(1.0-1.3).
[0027] A further improvement of the technical solution of the present invention is that the organic solvent used in step (1) is isopropanol, tert-butanol; or a mixture of an alcohol solution and N,N-dimethylformamide or N-methylpyrrolidone, wherein the alcohol solution is isopropanol or tert-butanol; the volume mass ratio of the mixed solution of the alcohol solution and N,N-dimethylformamide (DMF) or N-methylpyrrolidone (NMP) to the volume mass ratio of (R)-9-(2-hydroxypropyl)adenine is (1.5-15):1, preferably (1.5-5):1.0, and most preferably (2.0-4.0):1.0.
[0028] A further improvement of the technical solution of the present invention is that when the solvent used in step (1) is a mixture of an alcohol solution and N,N-dimethylformamide or N-methylpyrrolidone, the volume ratio of the alcohol to the volume of N,N-dimethylformamide or N-methylpyrrolidone is (0.3-10):1.
[0029] A further improvement of the technical solution of the present invention is that the catalyst in step (1) is a mixture of sodium tert-butoxide and magnesium chloride or a mixture of potassium tert-butoxide and magnesium chloride.
[0030] A further improvement of the technical solution of the present invention is as follows: the reaction solvent in step (1) is one or a mixture solvent of isopropanol, tert-butanol, N,N-dimethylformamide, and N-methylpyrrolidone; the reaction temperature is 60°C to 90°C, preferably 70°C to 85°C, and most preferably 75°C to 85°C; the reaction time is 3 to 12 hours, and preferably 4 to 8 hours.
[0031] A further improvement of the technical solution of the present invention is that: the acidolysis solvent in step (2) is concentrated hydrochloric acid with a concentration of 30-38% or concentrated hydrobromic acid with a concentration of 40-48%; or the acidolysis solvent is a mixed reagent of concentrated hydrochloric acid with a concentration of 30-38% and concentrated hydrobromic acid with a concentration of 40-48%; and the reaction temperature is 95-110°C.
[0032] A further improvement of the technical solution of the present invention is as follows: the acidolysis solvent in step (2) is concentrated hydrochloric acid or concentrated hydrobromic acid, wherein the molar ratio of acid to DEP is (6-15):1, preferably (8.0-12.0):1.0; the reaction time is 3-12 hours, preferably 5-8 hours; the acidolysis temperature is 95-110° C., wherein the preferred temperature is 98-105° C.;
[0033] A further improvement of the technical solution of the present invention is that the post-treatment in step (3) includes cooling and desalting, concentrating the solution, adjusting the base for crystallization, filtering and drying to obtain tenofovir.
[0034] Due to the adoption of the above technical solution, the technical effects achieved by the present invention are as follows:
[0035] The present invention uses a low boiling point solvent as a reaction solvent for preparing tenofovir diethyl ester. When the reaction is completed and concentrated, compared with N,N-dimethylformamide, the concentration temperature can be greatly reduced, the possibility of impurity generation can be reduced, and the concentration time can be shortened, thereby improving production efficiency and reducing production costs.
[0036] In addition, using sodium tert-butoxide and magnesium chloride as catalysts for the reaction of tenofovir diethyl can greatly save production costs compared with magnesium tert-butoxide or magnesium isopropoxide.
[0037] The present invention has the advantages of improving production efficiency, shortening production cycle, reducing production cost, etc., and can realize better commercial production of tenofovir. DETAILED DESCRIPTION
[0038] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below in conjunction with specific implementation methods.
[0039] The technical scheme is a method for synthesizing and preparing tenofovir, which uses a low-cost acidifying agent and a reaction solvent, thereby achieving the effect of reducing costs and also ensuring product quality.
[0040] The preparation method specifically comprises the following steps:
[0041] 1) Add (R)-9-(2-hydroxypropyl)adenine to an organic solvent solution containing a catalyst, and simultaneously add diethyl p-toluenesulfonyloxymethyl phosphate, and heat the reaction to generate tenofovir diethyl ester;
[0042] 2) Add strong acid to tenofovir diethyl ester and hydrolyze at elevated temperature to obtain tenofovir product;
[0043] 3) After the hydrolysis is completed, the reaction system is cooled and filtered to remove salt, and then the hydrochloric acid is concentrated and tenofovir is obtained after adjusting the base.
[0044] After step (3), a series of treatments are performed to obtain the tenofovir product. The specific treatment process includes cooling and desalting, concentrating the solution, adjusting the base and crystallizing, filtering and drying to obtain tenofovir.
[0045] Wherein, the catalyst in step (1) is tert-butoxide base, and the catalyst is at least one of potassium tert-butoxide and sodium tert-butoxide; wherein the molar ratio of (R)-9-(2-hydroxypropyl)adenine to tert-butoxide base is 1.00:(1.00-4.00), preferably 1.0:(1.5-2.5), and most preferably 1.0:(1.8-2.2).
[0046] In step (1), the catalyst is magnesium chloride, wherein the molar ratio of (R)-9-(2-hydroxypropyl)adenine to magnesium chloride is 1.0:(0.50-2.00), preferably 1.0:(0.8-1.6), and most preferably 1.0(1.0-1.2); the molar ratio of (R)-9-(2-hydroxypropyl)adenine to diethyl tosyloxymethyl phosphate is 1.0:(1.0-2.0), preferably 1.0:(1.0-1.5), and most preferably 1.0:(1.0-1.3).
[0047] The organic solvent used in step (1) is isopropanol, tert-butanol; or a mixture of an alcohol solution and N,N-dimethylformamide or N-methylpyrrolidone, wherein the alcohol solution is isopropanol or tert-butanol; the volume mass ratio of the mixed solution of the alcohol solution and N,N-dimethylformamide (DMF) or N-methylpyrrolidone (NMP) to the volume mass ratio of (R)-9-(2-hydroxypropyl)adenine is (1.5-15):1, preferably (1.5-5):1.0, and most preferably (2.0-4.0):1.0.
[0048] When the solvent used in step (1) is a mixture of an alcohol solution and N,N-dimethylformamide or N-methylpyrrolidone, the volume ratio of the alcohol solution to the volume of N,N-dimethylformamide or N-methylpyrrolidone is (0.3-10):1.
[0049] In step (1), the catalyst is a mixture of sodium tert-butoxide and magnesium chloride or a mixture of potassium tert-butoxide and magnesium chloride.
[0050] The reaction solvent of step (1) is one or a mixture of isopropanol, tert-butanol, N,N-dimethylformamide, and N-methylpyrrolidone; the reaction temperature is 60°C to 90°C, preferably 70°C to 85°C, and most preferably 75°C to 85°C; the reaction time is 3 to 12 hours, preferably 4 to 8 hours.
[0051] The acidolysis solvent in step (2) is concentrated hydrochloric acid with a concentration of 30-38% or concentrated hydrobromic acid with a concentration of 40-48%; or the acidolysis solvent is a mixed reagent of concentrated hydrochloric acid with a concentration of 30-38% and concentrated hydrobromic acid with a concentration of 40-48%; the reaction temperature is 95-110°C.
[0052] The acidolysis solvent of step (2) is concentrated hydrochloric acid or concentrated hydrobromic acid, wherein the molar ratio of acid to DEP is (6-15):1, preferably (8.0-12.0):1.0; the reaction time is 3-12 hours, preferably 5-8 hours; the acidolysis temperature is 95-110°C, wherein the preferred temperature is 98-105°C.
[0053] The preparation method of the technical solution can achieve the reduction of production cost from both the production raw materials and the production process. The method uses sodium tert-butoxide and magnesium chloride as catalysts for the DEP reaction, which can greatly save production costs compared with magnesium tert-butoxide or magnesium isopropoxide. The raw materials of the method are low-boiling point solvents, which can greatly reduce the concentration temperature, reduce the possibility of impurity generation, and shorten the concentration time, thereby improving production efficiency and reducing production costs.
[0054] The following are specific embodiments:
[0055] Example 1: Preparation of HPA with reference to WO0208241
[0056] Referring to Example 1b of WO0208241, HPA was prepared by adding 500 g to DMF (524 ml), adding R-propylene carbonate (430.64 g) and sodium hydroxide (5.92 g), heating to 130 ° C for overnight reaction. After the reaction was completed, it was cooled to 100 ° C, 1.70 L of toluene was added, and then kept warm at 100-110 ° C, methylsulfonic acid (58.75 g) was added, and then 1.4 L of toluene was added and stirred evenly, and then the temperature was gradually lowered to 0-5 ° C, kept warm and stirred for 1 hour, and the solid was filtered out. The filter cake was rinsed with acetone and dried in vacuo at 80 ° C to obtain 547.10 g (yield: 76.53%).
[0057] Example 2: Preparation of Tenofovir (PMPA) (Isopropyl Alcohol as Solvent)
[0058] PMPA was prepared using the HPA prepared in Example 1: 90 ml of isopropanol was weighed and added to a three-necked reaction bottle, 14.77 g (1.00 eq) of anhydrous magnesium chloride was added, and the temperature was raised to 63-65° C. with stirring, and 32.84 g (2.20 eq) of sodium tert-butoxide was slowly added under stirring. After the addition, the mixture was kept warm and stirred for 1 hour. HPA 30.00 g (1.00 eq) was added to the system, and the mixture was kept warm and stirred for 30 min. Then, 61.56 g of DESMP (1.23 eq) was added dropwise over a 30-60 min period.
[0059] After the dropwise addition is completed, the temperature is raised to 75-85°C and stirred for 6 hours. After the reaction is completed, the temperature is lowered to 10-20°C, 11.19g of glacial acetic acid is added dropwise, and stirred for 1 hour after the dropwise addition is completed. The temperature is raised to 40-50°C and the liquid is concentrated under reduced pressure. After the liquid is concentrated, 157.26g (10.00eq) of concentrated hydrochloric acid (36-38%) is added to the system, stirred at 0-10°C for 1 hour, and then the precipitated solid is filtered out. The filtrate is heated to 98-105°C and refluxed for 6 hours to monitor the completion of the reaction.
[0060] The reaction solution was concentrated under reduced pressure at 80-85°C to recover the hydrochloric acid solution, 90 ml of purified water was added to the concentrate, stirred to dissolve, and then the pH value was adjusted to 2.5-3.0 with 30% sodium hydroxide. The mixture was cooled to 0-10°C with stirring and stirred for 5 hours. The solid was filtered out, the filter cake was rinsed with purified water 2-3 times, and dried. The filter cake was vacuum dried at 70-80°C to obtain PMPA, which weighed 34.76 g (yield: 77.94%).
[0061] Example 3: Preparation of Tenofovir (PMPA) (tert-butyl alcohol as solvent)
[0062] Measure 60 ml of tert-butanol and add it to a three-necked reaction bottle, add 9.86 g (1.00 eq) of anhydrous magnesium chloride, stir and heat to 60-65°C, slowly add 21.89 g (2.20 eq) of sodium tert-butoxide under stirring, keep warm and stir for 1 hour after the addition, add 20.00 g (1.00 eq) of HPA to the system, keep warm and stir for 30 min, then control the temperature and gradually decrease DESMP (1.23 eq), and add dropwise over 30-60 min.
[0063] After the addition is completed, the temperature is raised to 78-85°C and stirred for 5 hours. After the reaction is completed, the temperature is lowered to 28-32°C, 7.46g of glacial acetic acid is added dropwise, and stirred for 1 hour after the addition is completed. The temperature is raised to 40-50°C and the liquid is concentrated under reduced pressure. After the liquid is concentrated, 104.84g (10.00eq) of concentrated hydrochloric acid (36-38%) is added to the system, stirred at 0-10°C for 1 hour, the precipitated solid is filtered out, and the filtrate is heated to 98-105°C and refluxed for 5-8 hours to monitor the completion of the reaction.
[0064] The reaction solution was concentrated under reduced pressure at 80-85°C to recover the hydrochloric acid solution, 60 ml of purified water was added to the concentrate and stirred to dissolve, the pH value was adjusted to 2.5-3.0 with 30% sodium hydroxide for crystallization, the temperature was controlled at 0-10°C and stirred for 5 hours for crystallization, the solid was filtered out, the filter cake was rinsed with purified water 2-3 times, and dried, and the filter cake was vacuum dried at 70-80°C to obtain PMPA, weighing 22.82 g (yield: 76.75%).
[0065] Example 4: Preparation of Tenofovir (PMPA) (mixed liquid of isopropanol and DMF as solvent)
[0066] Measure 25 ml of DMF and 75 ml of isopropanol and add them to a three-necked reaction bottle, weigh 24.64 g (1.00 eq) of anhydrous magnesium chloride, stir and heat to 60-65°C, slowly add 54.72 g (2.20 eq) of sodium tert-butoxide, and keep stirring for 1 hour after the addition. Add 50.00 g (1.00 eq) of HPA to the system, keep stirring for 30 min, and then control the temperature to gradually decrease 102.60 g of DESMP (1.23 eq), and add dropwise over 30-60 min.
[0067] After the addition is completed, the temperature is raised to 75-85°C and stirred for reaction for 5 hours. After the reaction is completed, the temperature is lowered to 28-32°C, 18.65g of glacial acetic acid is added dropwise, and stirred for 1 hour after the addition is completed. The temperature is raised to 40-50°C and the liquid is concentrated under reduced pressure. When no liquid is dripped, the temperature is raised to 78-82°C and the remaining liquid is further concentrated. After the liquid is concentrated, 262.10g (10.00eq) of concentrated hydrochloric acid (36-38%) is added to the system, and stirred at 0-10°C for 1 hour. The precipitated solid is filtered out, and the filtrate is heated to 98-105°C and refluxed for reaction for 6 hours to monitor the completion of the reaction.
[0068] The reaction solution was concentrated under reduced pressure at 80-85°C to recover the hydrochloric acid solution, 150 ml of purified water was added to the concentrate and stirred to dissolve, the pH value was adjusted to 2.5-3.0 with 30% sodium hydroxide for crystallization, the temperature was controlled at 0-10°C and stirred for 5 hours for crystallization, the solid was filtered out, the filter cake was rinsed with purified water 2-3 times, and dried, and the filter cake was vacuum dried at 70-80°C to obtain PMPA, weighing 55.73 g (yield: 74.98%).
[0069] Example 5: Preparation of Tenofovir (PMPA) (Mixed liquid of tert-butyl alcohol and DMF as solvent)
[0070] Measure 20 ml of DMF and 80 ml of tert-butanol and add them into a three-necked reaction bottle, weigh 14.78 g (1.00 eq) of anhydrous magnesium chloride, stir and heat to 60-65°C, slowly add 32.83 g (2.20 eq) of sodium tert-butoxide, and keep stirring for 1 hour after the addition. Add 30.00 g (1.00 eq) of HPA to the system, keep stirring for 30 min, and then control the temperature to gradually decrease 61.56 g of DESMP (1.23 eq), and add dropwise over 30-60 min.
[0071] After the addition is completed, the temperature is raised to 75-85°C and stirred for reaction for 5 hours. After the reaction is completed, the temperature is lowered to 28-32°C, 11.19g of glacial acetic acid is added dropwise, and stirred for 1 hour after the addition is completed. The temperature is raised to 40-50°C and the liquid is concentrated under reduced pressure. When no liquid is dripped, the temperature is raised to 78-82°C and the remaining liquid is concentrated. After the liquid is concentrated, 262.10g (10.00eq) of concentrated hydrochloric acid (36-38%) is added to the system, and stirred at 0-10°C for 1 hour. The precipitated solid is filtered out, and the filtrate is heated to 98-105°C and refluxed for reaction for 6 hours to monitor the completion of the reaction.
[0072] The reaction solution was concentrated under reduced pressure at 80-85°C to recover the hydrochloric acid solution, 90 ml of purified water was added to the concentrate and stirred to dissolve, the pH value was adjusted to 2.5-3.0 with 30% sodium hydroxide for crystallization, the temperature was controlled at 0-10°C and stirred for 5 hours for crystallization, the solid was filtered out, the filter cake was rinsed with purified water 2-3 times, and dried, and the filter cake was vacuum dried at 70-80°C to obtain PMPA, weighing 32.68 g (yield: 73.28%).
[0073] In the above five embodiments, HPA was prepared in Embodiment 1, and tenofovir was prepared using different solvents in Embodiments 2-5. The yields were able to meet the requirements of industrial production, and the production costs corresponding to the above embodiments were relatively low. Therefore, they are more suitable for commercial and industrial production.
[0074] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A method for synthesizing tenofovir, characterized in that: The following steps are involved: 1) Add (R)-9-(2-hydroxypropyl)adenine to an organic solvent solution containing a catalyst, and simultaneously add diethyl p-toluenesulfonyloxymethyl phosphate, and heat the reaction to generate tenofovir diethyl ester; 2) Add strong acid to tenofovir diethyl ester and hydrolyze at elevated temperature to obtain tenofovir product; 3) After the hydrolysis is completed, the reaction system is cooled and filtered to remove salt, and then the hydrochloric acid is concentrated and tenofovir is obtained after alkali adjustment.
2. The method for synthesizing tenofovir according to claim 1, characterized in that: In step (1), the catalyst is tert-butoxide, and the catalyst is at least one of potassium tert-butoxide and sodium tert-butoxide; wherein the molar ratio of (R)-9-(2-hydroxypropyl)adenine to tert-butoxide is 1.00:(1.00-4.00), preferably 1.0:(1.5-2.5), and most preferably 1.0:(1.8-2.2).
3. The method for synthesizing tenofovir according to claim 1, characterized in that: In step (1), the catalyst is magnesium chloride, wherein the molar ratio of (R)-9-(2-hydroxypropyl)adenine to magnesium chloride is 1.0:(0.50-2.00), preferably 1.0:(0.8-1.6), and most preferably 1.0(1.0-1.2); the molar ratio of (R)-9-(2-hydroxypropyl)adenine to diethyl tosyloxymethyl phosphate is 1.0:(1.0-2.0), preferably 1.0:(1.0-1.5), and most preferably 1.0:(1.0-1.3).
4. The method for synthesizing tenofovir according to claim 1, characterized in that: The organic solvent used in step (1) is isopropanol, tert-butanol; or a mixture of an alcohol solution and N,N-dimethylformamide or N-methylpyrrolidone, wherein the alcohol solution is isopropanol or tert-butanol; the volume mass ratio of the mixed solution of the alcohol solution and N,N-dimethylformamide (DMF) or N-methylpyrrolidone (NMP) to the volume mass ratio of (R)-9-(2-hydroxypropyl)adenine is (1.5-15):1, preferably (1.5-5):1.0, and most preferably (2.0-4.0):1.
0.
5. The method for synthesizing tenofovir according to claim 1, characterized in that: When the solvent used in step (1) is a mixture of an alcohol solution and N,N-dimethylformamide or N-methylpyrrolidone, the volume ratio of the alcohol to the volume of N,N-dimethylformamide or N-methylpyrrolidone is (0.3-10):
1.
6. The method for synthesizing tenofovir according to claim 5, characterized in that: The catalyst in step (1) is a mixture of sodium tert-butoxide and magnesium chloride or a mixture of potassium tert-butoxide and magnesium chloride.
7. The method for synthesizing tenofovir according to claim 5, characterized in that: The reaction solvent of step (1) is one or a mixture of isopropanol, tert-butanol, N,N-dimethylformamide, and N-methylpyrrolidone; the reaction temperature is 60°C to 90°C, preferably 70°C to 85°C, and most preferably 75°C to 85°C; the reaction time is 3 to 12 hours, and preferably 4 to 8 hours.
8. The method for synthesizing tenofovir according to claim 1, characterized in that: The acidolysis solvent in step (2) is concentrated hydrochloric acid with a concentration of 30-38% or concentrated hydrobromic acid with a concentration of 40-48%; or the acidolysis solvent is a mixed reagent of concentrated hydrochloric acid with a concentration of 30-38% and concentrated hydrobromic acid with a concentration of 40-48%; the reaction temperature is 95-110°C.
9. The method for synthesizing tenofovir according to claim 1, characterized in that: The acidolysis solvent of step (2) is concentrated hydrochloric acid or concentrated hydrobromic acid, wherein the molar ratio of acid to DEP is (6-15):1, preferably (8.0-12.0):1.0; the reaction time is 3-12 hours, preferably 5-8 hours; the acidolysis temperature is 95-110°C, wherein the preferred temperature is 98-105°C.
10. The method for synthesizing tenofovir according to claim 1, characterized in that: The post-treatment in step (3) includes cooling to remove salt, concentrating the solution, adjusting the base to crystallize, filtering and drying to obtain tenofovir.
